View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2019	Mar. 01, 2020	Jun. 30, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	FLGT
Entity Registrant Name	FULGENT GENETICS, INC.
Entity Central Index Key	0001674930
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,564,971
Entity Public Float			$ 38.8
Entity File Number	001-37894
Entity Tax Identification Number	81-2621304
Entity Address, Address Line One	4978 Santa Anita Avenue
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Temple City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91780
City Area Code	626
Local Phone Number	350-0537
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Certain portions of the registrant’s definitive proxy statement for its 2020 annual meeting of stockholders are incorporated by reference in Part III of this report.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 11,965	$ 6,736
Marketable securities	16,304	24,298
Trade accounts receivable, net of allowance for doubtful accounts of $751 and $590, as of December 31, 2019 and 2018, respectively	6,555	5,948
Other current assets	2,255	2,561
Total current assets	37,079	39,543
Marketable securities, long-term	41,947	6,386
Equity method investments	872	1,512
Fixed assets, net	5,974	6,446
Operating lease right-of-use asset	2,633
Other long-term assets	251	17
Total assets	88,756	53,904
Current liabilities
Accounts payable	1,581	1,313
Accrued liabilities	1,333	1,259
Income tax payable	24
Contract liabilities	365	166
Operating lease liabilities, short-term	420
Total current liabilities	3,723	2,738
Operating lease liabilities, long-term	2,256
Other long-term liabilities		14
Total liabilities	5,979	2,752
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 21,483 and 18,172 shares issued and outstanding at December 31, 2019 and 2018, respectively	2	2
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at December 31, 2019 and 2018
Additional paid-in capital	146,058	114,203
Accumulated other comprehensive income (loss)	146	(35)
Accumulated deficit	(63,429)	(63,018)
Total stockholders’ equity	82,777	51,152
Total liabilities and stockholders’ equity	$ 88,756	$ 53,904

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 751	$ 590
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	21,483,000	18,172,000
Common stock, shares outstanding	21,483,000	18,172,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue	$ 8,387	$ 10,347	$ 8,424	$ 5,370	$ 5,673	$ 5,625	$ 5,400	$ 4,653	$ 32,528	$ 21,351
Cost of revenue	3,634	3,885	3,620	2,968	2,769	2,612	2,544	2,772	14,107	10,697
Gross profit	4,753	6,462	4,804	2,402	2,904	3,013	2,856	1,881	18,421	10,654
Operating expenses:
Research and development	1,795	1,744	1,574	1,424	1,426	1,438	1,212	1,458	6,537	5,534
Selling and marketing	1,635	1,687	1,304	1,272	1,128	1,115	1,279	1,130	5,898	4,652
General and administrative	1,732	1,522	1,631	1,529	1,379	1,306	1,366	1,487	6,414	5,538
Total operating expenses	5,162	4,953	4,509	4,225	3,933	3,859	3,857	4,075	18,849	15,724
Operating income (loss)	(409)	1,509	295	(1,823)	(1,029)	(846)	(1,001)	(2,194)	(428)	(5,070)
Interest and other income, net	249	189	192	207	98	143	98	95	837	434
Income (loss) before income taxes and equity loss in investee	(160)	1,698	487	(1,616)	(931)	(703)	(903)	(2,099)	409	(4,636)
Provision for income taxes	(38)	61	7	13	888	(318)	(100)	(434)	43	36
Income (loss) before equity loss in investee	(122)	1,637	480	(1,629)	(1,819)	(385)	(803)	(1,665)	366	(4,672)
Equity loss in investee	(174)	(175)	(149)	(279)	(234)	(210)	(246)	(245)	(777)	(935)
Net income (loss)	$ (296)	$ 1,462	$ 331	$ (1,908)	$ (2,053)	$ (595)	$ (1,049)	$ (1,910)	$ (411)	$ (5,607)
Net loss per common share:
Basic	$ (0.01)	$ 0.08	$ 0.02	$ (0.10)	$ (0.11)	$ (0.03)	$ (0.06)	$ (0.11)	$ (0.02)	$ (0.31)
Diluted	$ (0.01)	$ 0.08	$ 0.02	$ (0.10)	$ (0.11)	$ (0.03)	$ (0.06)	$ (0.11)	$ (0.02)	$ (0.31)
Weighted-average common shares:
Basic									18,709	17,978
Diluted									18,709	17,978

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (411)	$ (5,607)
Other comprehensive income (loss)
Foreign currency translation loss	(17)	(44)
Net unrealized gain on marketable securities, net of tax	198	53
Comprehensive loss	$ (230)	$ (5,598)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Underwriters	Equity Distribution Agreement	Stockholders' Equity	Stockholders' Equity Underwriters	Stockholders' Equity Equity Distribution Agreement	Additional Paid-In Capital	Additional Paid-In Capital Underwriters	Additional Paid-In Capital Equity Distribution Agreement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2017	$ 54,178			$ 2			$ 111,884			$ (44)	$ (57,664)
Beginning Balance, Shares at Dec. 31, 2017				17,847,000
Equity-based compensation	2,304						2,304
Exercise of common stock options	15						15
Exercise of common stock options, Shares				40,000
Restricted stock awards, Shares				285,000
Cumulative effect of accounting change	327										327
Cumulative tax effect of accounting change	(74)										(74)
Other comprehensive gain (loss), net	9									9
Net income (loss)	(5,607)										(5,607)
Ending Balance at Dec. 31, 2018	$ 51,152			$ 2			114,203			(35)	(63,018)
Ending Balance, Shares at Dec. 31, 2018	18,172,000			18,172,000
Equity-based compensation	$ 3,209						3,209
Exercise of common stock options	38						38
Exercise of common stock options, Shares				100,000
Restricted stock awards, Shares				434,000
Issuance of common stock		$ 27,650	$ 979					$ 27,650	$ 979
Issuance of common stock, Shares					2,674,000	104,000
Repurchases of capital stock	(21)						(21)
Repurchases of capital stock, Shares				(1,000)
Other comprehensive gain (loss), net	181									181
Net income (loss)	(411)										(411)
Ending Balance at Dec. 31, 2019	$ 82,777			$ 2			$ 146,058			$ 146	$ (63,429)
Ending Balance, Shares at Dec. 31, 2019	21,483,000			21,483,000

Consolidated Statements of Stockholders' Equity (Parenthetical) - Weighted-Average - Common Stock	Dec. 31, 2019 $ / shares
Underwriters
Selling price per share	$ 10.34
Equity Distribution Agreement
Selling price per share	$ 9.37

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flow from operating activities:
Net loss	$ (411)	$ (5,607)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity-based compensation	3,209	2,304
Depreciation	2,107	2,163
Noncash lease expense	413
Loss on disposal of fixed asset	11	88
Amortization of premium of marketable securities	106	297
Provision for bad debt	189	309
Deferred taxes	(21)	36
Equity loss in investee	777	935
Other	52	44
Changes in operating assets and liabilities:
Accounts receivable	(839)	(1,970)
Other current and long-term assets	374	91
Accounts payable	(329)	102
Accrued liabilities and other current liabilities	264	533
Income tax payable	24
Operating lease liabilities	(409)
Net cash provided by (used in) operations	5,517	(675)
Cash flow from investing activities:
Purchases of fixed assets	(1,182)	(2,322)
Purchase of marketable securities	(52,077)	(24,187)
Maturities of marketable securities	24,350	27,969
Purchase of equipment contributed to Equity Method Investee	(137)	(510)
Net cash (used in) provided by investing activities	(29,046)	950
Cash flow from financing activities:
Proceeds from public offerings of common stock, net of issuance costs	28,758
Proceeds from exercise of stock options	38	15
Repurchases of capital stock	(21)
Net cash provided by financing activities	28,775	15
Effect of exchange rate changes on cash and cash equivalents	(17)	(44)
Net increase in cash and cash equivalents	5,229	246
Cash and cash equivalents at beginning of period	6,736	6,490
Cash and cash equivalents at end of period	11,965	6,736
Supplemental disclosures of cash flow information:
Income taxes paid	20	1
Supplemental disclosures of non-cash investing and financing activities:
Purchases of fixed assets in accounts payable	557	$ 85
Operating lease right-of-use assets obtained in exchange for lease liabilities	110
Public offerings costs included in accounts payable	$ 129

Overview and Basis of Presentation

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Overview and Basis of Presentation

Note 1. Overview and Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These financial statements include the assets, liabilities, revenues and expenses of all wholly-owned subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries (collectively referred to as the “Company,” unless otherwise noted or the context otherwise requires), is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care (the “Diagnostics business”). In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library. The Company’s test menu currently includes single-gene tests and pre-established, multi-gene, disease-specific panels that collectively test for many genetic conditions, including various cancers, cardiovascular diseases, neurological disorders and pediatric conditions. The Company’s existing customer base consists primarily of hospitals and medical institutions, which are typically frequent and high-volume users of genetic tests and which often pay the Company directly for its tests.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments, assumptions and decisions that affect the reported amounts and related disclosures, including the selection of appropriate accounting policies and the assumptions on which to base accounting estimates. In making these estimates and assumptions and reaching these decisions, the Company applies judgment based on its understanding and analysis of the relevant circumstances, including historical data and experience available at the date of the accompanying consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances. Actual results could differ from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) the valuation of equity-based awards.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and money market accounts. Cash equivalents are stated at fair value.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are stated at the amount the Company expects to collect. The Company performs credit evaluations of its customers and generally does not require collateral. The Company establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information that assists in management’s evaluation. The Company writes off accounts receivable following a review by management and a determination that the receivable is uncollectible.

A roll-forward of the activity in the Company’s allowance for doubtful accounts is as follows:

	December 31,
	2019			2018
	(in thousands)
Allowance for doubtful accounts at beginning of year	$	590		$	287
Bad debt expense		189			309
Deductions		(28	)		(6	)
Allowance for doubtful accounts at end of year	$	751		$	590

Marketable Securities

All marketable securities, which consist of debt securities, United States Treasury and U.S. government agency securities, have been classified as “available for sale” and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders’ equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on marketable securities are included in other income (expense), net. The cost of any marketable securities sold is based on the specific-identification method. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in interest income. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.

The Company regularly evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and record a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.

Fair Value of Financial Instruments

The Company's financial instruments consist principally of cash and cash equivalents, marketable securities, accounts receivable and accounts payable. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to their short maturities. Fair value of marketable securities is disclosed in Note 4, Fair Value Measurements, to the accompanying consolidated financial statements.

Concentrations of Credit Risk, Customers and Suppliers

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, accounts receivable and marketable securities, which consist of debt securities, and cash equivalents. As of December 31, 2019, substantially all of the Company’s cash and cash equivalents were deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash and cash equivalents are held.

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. Aggregating customers that are under common control or are affiliates, one customer comprised 28% of total revenue in the year ended December 31, 2019, and one customer comprised 13% of total revenue in the year ended December 31, 2018. No customer comprised at least 10% of total accounts receivable as of December 31, 2019. One customer comprised 18% of total accounts receivable as of December 31, 2018.

Revenue from the U.S. government was less than 10% of total revenue in each of the years ended December 31, 2019 and 2018.

The Company relies on a limited number of suppliers for certain laboratory substances used in the chemical reactions incorporated into its processes, referred to as reagents, as well as for the sequencers and various other equipment and materials it uses in its laboratory operations. In particular, the Company relies on a sole supplier for the next generation sequencers and associated reagents it uses to perform its genetic tests and as the sole provider of maintenance and repair services for these sequencers. The Company’s laboratory operations would be interrupted if it encounters delays or difficulties securing these reagents, sequencers, other equipment or materials or maintenance and repair services, which could occur for a variety of reasons, including if the Company needs a replacement or temporary substitute for any of its limited or sole suppliers and is not able to locate and make arrangements with an acceptable replacement or temporary substitute. The Company believes there are currently only a few other manufacturers that are capable of supplying and servicing some of the equipment and other materials necessary for its laboratory operations, including sequencers and various associated reagents.

Equity Method Investments

The Company uses the equity method to account for investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. The Company's proportionate share of the net income or loss of these companies is included in consolidated net earnings. Judgments regarding the level of influence over each equity method investment include consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions.

The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that a decline in value has occurred that is other than temporary. Evidence considered in this evaluation includes, but would not necessarily be limited to, the financial condition and near-term prospects of the investee, recent operating trends and forecasted performance of the investee, market conditions in the geographic area or industry in which the investee operates and the Company’s strategic plans for holding the investment in relation to the period of time expected for an anticipated recovery of its carrying value. If the investments is determined to have a decline in value deemed to be other than temporary it is written down to estimated fair value.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included as operating lease right-of-use (“ROU”) assets, operating lease liabilities, short-term, and operating lease liabilities, long-term, on the Company’s Consolidated Balance Sheets.

ROU lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating ROU lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments since its leases do not provide an implicit rate. The ROU lease asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Fixed Assets

Fixed assets are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, which is generally between three and five years. Leasehold improvements are capitalized and amortized over the shorter of their expected lives or the applicable lease term, including renewal options, if available. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.

Software for Internal Use

The Company capitalizes certain costs incurred to purchase computer software for internal use. These costs include purchased software packages for Company use. Capitalized computer software costs are amortized over the estimated useful life of the computer software, which is generally three years. Internally developed software costs are capitalized after management has committed to funding the project, it is probable that the project will be completed and the software will be used for its intended function. Costs that do not meet that criteria and costs incurred on projects in the preliminary and post-implementation phases are expensed as incurred.

Impairment of Long-Lived Assets

The Company evaluates the carrying amount of its long-lived assets whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of an asset and its eventual disposition is less than the carrying amount of the asset. To date, there have been no such impairment losses.

Reporting Segment and Geographic Information

Reporting segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company views its operations and manages its business in one reporting segment.

Revenue Recognition

The Company generates revenue from sales of its genetic tests. The Company currently receives payments from: hospitals and medical institutions with which it has direct-bill relationships; research institutions; individual patients and third-party payors.

The Company’s test results are delivered electronically, and as such there are no shipping and handling fees incurred by it or billed to customers. The Company’s sales are typically exempt from state sales taxation due to the nature of the results delivered. As a result, the Company currently does not charge customers state sales tax and continues to assess.

Effective January 1, 2018, the Company began recognizing revenue in accordance with FASB ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company adopted ASC 606 utilizing the modified retrospective method, meaning the cumulative effect of applying the standard was recognized to opening retained earnings as of January 1, 2018. To reflect the impact of the adoption, the Company recorded an adjustment of $327,000 to beginning accumulated deficit and accounts receivable and an adjustment of ($74,000) to beginning accumulated deficit and deferred taxes. Under ASC 606, the Company recognizes revenue in an amount that reflects the consideration to which it expects to be entitled in exchange for the transfer of promised goods or services to customers. To determine revenue recognition for contracts with customers that are within the scope of ASC 606, the Company performs the following steps: (1) identifies the contract with the customer, (2) identifies the performance obligations in the contract, (3) determines the transaction price, (4) allocates the transaction price to the performance obligations in the contract, and (5) recognizes revenue when (or as) the entity satisfies a performance obligation.

Performance Obligations

Genetic Testing Services

Clinical – Institutional and Patient Direct Pay

The Company’s clinical institutional contracts included within genetic testing services typically have a single performance obligation to deliver genetic testing services to the ordering facility or patient. Some arrangements involve the delivery of genetic testing services to research institutions, which we refer to as “sequencing as a service.” In arrangements with hospitals, patients who pay directly, medical or research institutions, the transaction price is stated within the contract and is therefore fixed consideration. For most of the Company’s clinical volume, we identified the hospital, patients, medical or research institutions as the customer in Step 1 of the model and have determined a contract exists with those customers in Step 1. As these contracts typically have a single performance obligation, no allocation of the transaction price is required in Step 4 of the model. Control over genetic testing services is transferred to the Company’s ordering facility at a point in time. Specifically, we determined the customer obtains control of the promised service upon delivery of test results.

Clinical – Insurance

The Company’s clinical insurance contracts included within genetic testing services typically have a single performance obligation to deliver genetic testing services to the ordering facility or patient. For most of the Company’s clinical insurance volume, we identified the patient as the customer in Step 1 of the model and have determined a contract exists with the patient in Step 1. In arrangements with insurance patients, the transaction price is stated within the contract, however, we accept payments from third-party payors that are less than the contractually stated price and is therefore variable consideration. In developing the estimate of variable consideration, we utilize the expected value method under a portfolio approach. The Company’s estimate requires significant judgment and is developed using historical reimbursement data from payors and patients, as well as known current reimbursement trends not reflected in the historical data. As these contracts typically have a single performance obligation, no allocation of the transaction price is required in Step 4 of the model. Control over genetic testing services is transferred to the Company’s ordering physicians at a point in time. Specifically, we determined the customer obtains control of the promised service upon delivery of the test results.

Certain incremental costs pertaining to both clinical insurance and institutional, such as commissions, are incurred in obtaining clinical contracts. Historically contract costs have not been significant to the financial statements. We have elected to utilize the practical expedient to expense incremental costs of obtaining a contract that meet the capitalization criteria, as the amortization period of any contract acquisition asset would be one year or less due to the short-term nature of the customer life.

Significant Judgments and Contract Estimates

Genetic Testing Services

Accounting for clinical insurance contracts includes estimation of the transaction price, defined as the amount we expect to be entitled to receive in exchange for providing the services under the contract. Due to the Company’s out-of-network status with the majority of payors, estimation of the transaction price represents variable consideration. In order to estimate variable consideration, we utilize a portfolio approach in which payors with similar reimbursement experience are grouped into portfolios. The Company’s estimates of variable consideration are based primarily on historical reimbursement data. Certain assumptions will also be adjusted based on known and anticipated factors not reflected in the historical reimbursement data. We monitor these accrual estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the initial accrual estimate and any subsequent revision to the estimate contain uncertainty and require the use of judgment in the estimation of the transaction price and application of the constraint for variable consideration. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect revenue and earnings in the period such variances become known.

Contract Liabilities

Payments received in advance of services rendered are recorded as contract liabilities and are subsequently recognized as revenue in the period in which the applicable revenue recognition criteria, as described above, are met.

Overhead Expenses

The Company allocates overhead expenses, such as rent and utilities, to cost of revenue and operating expense categories based on headcount. As a result, an overhead expense allocation is reflected in cost of revenue and each operating expense category.

Cost of Revenue

Cost of revenue reflects the aggregate costs incurred in delivering test results and consists of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; costs of laboratory supplies; depreciation of laboratory equipment; amortization of leasehold improvements and allocated overhead. Costs associated with performing tests are recorded as tests are processed.

Research and Development Expenses

Research and development expenses represent costs incurred to develop the Company’s technology and future tests. These costs consist of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; laboratory supplies; consulting costs and allocated overhead. The Company expenses all research and development costs in the periods in which they are incurred.

Selling and Marketing Expenses

Selling and marketing expenses consist of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; customer service expenses; direct marketing expenses; educational and promotional expenses; market research and analysis and allocated overhead. The Company expenses all selling and marketing costs as incurred.

General and Administrative Expenses

General and administrative expenses include executive, finance and accounting, legal and human resources functions. These expenses consist of: personnel costs, including salaries, employee benefit costs, bonuses and equity-based compensation expenses; audit and legal expenses; consulting costs and allocated overhead. The Company expenses all general and administrative expenses as incurred.

Income Taxes

Income taxes are accounted for under the asset and liability method. The Company provides for federal, state and foreign income taxes currently payable, as well as for taxes deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount with a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in its consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense.

Equity-Based Compensation

The Company grants various types of equity-based awards to its employees, consultants and non-employee directors. Equity-based compensation costs are reflected in the accompanying statements of operations based upon each award recipient’s role with the Company. The Company primarily grants to its employees restricted stock unit (RSU) awards that generally vest over a specified period of time upon the satisfaction of service-based conditions. The Company measures compensation expense for equity-based awards granted to employees based on the fair value of the award on the grant date of the award. Compensation expense for employee RSU awards with a service-based vesting condition is recognized ratably over the vesting period of the award.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using average rates in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in other comprehensive income (loss) as a component in the accompanying Consolidated Statements of Stockholders’ Equity. The Company’s subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from the remeasurements are included in interest and other income, net in the accompanying Consolidated Statements of Operations. Gains and losses from these remeasurements were not significant in the year ended December 31, 2019.

Comprehensive Loss

Comprehensive loss is comprised of net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gain or loss on marketable securities and foreign currency translation adjustments from its subsidiaries not using the U.S. dollar as their functional currency. The Company did not have reclassifications from other comprehensive income or loss to net loss during the year ended December 31, 2019.

Basic and Diluted Net Loss per Share

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common share equivalents outstanding during the period. Because the Company has reported a net loss attributable to common stockholders for all periods presented, diluted net loss per common share is the same as basic net loss per common share for these periods.

Emerging Growth Company

Pursuant to the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), a company constituting an “emerging growth company” is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company, but has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies.

Disaggregation of Revenue

The Company classifies its customers into three payor types, Clinical Institutional, Patients who pay directly or Clinical Insurance, as we believe this best depicts how the nature, amount, timing, and uncertainty of the Company’s revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the years ended December 31, 2019 and 2018.

	Year Ended December 31,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	31,284	$	19,980
Patient		539		547
Insurance		705		824
Total Revenue	$	32,528	$	21,351

There was no material variable consideration recognized in the current period that relates to performance obligations that were completed in the prior period.

Contract Balances

Receivables from contracts with customers - As of December 31, 2019 and 2018, receivables from contracts with customers were approximately $6.6 and $5.9 million, respectively, and are included within Trade accounts receivable on the Consolidated Balance Sheets.

Contracts assets and liabilities - As of December 31, 2019 and 2018, contract assets from contracts with customers were $150,000, associated with contract execution and included in other current assets in the accompanying Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment prior to completing its obligation to transfer goods or services to a customer. The Company had $365,000 and $166,000 of contract liabilities as of December 31, 2019 and 2018, respectively. Revenues of $59,000 and $16,000 for the years ended December 31, 2019 and 2018, respectively, related to contract liabilities at the beginning of the respective periods were recognized.

Reclassifications

Certain reclassifications have been made to the consolidated financial statements of the prior year in order to conform to the current year presentation. These reclassifications had no impact on shareholder’s equity or net income for the year ended December 31, 2018. In the Consolidated Balance Sheet for the year ended December 31, 2018, the financial statement line item Contract liabilities was reclassified from Accrued Liabilities.

Transaction Price Allocated to Future Performance Obligations

ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as December 31, 2019. ASC 606 provides certain practical expedients that limit the requirement to disclose the aggregate amount of transaction price allocated to unsatisfied performance obligations.

The Company applied the practical expedient to not disclose the amount of transaction price allocated to unsatisfied performance obligations when the performance obligation is part of a contract that has an original expected duration of one year or less. The Company does not have material future obligations associated with Genetic Testing Services that extend beyond one year.

Recent Accounting Pronouncements

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures.

ASU No. 2016-01

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, including a provision that requires equity investments (except for investments accounted for under the equity method of accounting) to be measured at fair value, with changes in fair value recognized in current earnings. The ASU was effective for the Company in the first quarter of 2018. The adoption of this update did not have a material impact on the Company’s consolidated financial statements or disclosures.

ASU No. 2016-02

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC 840, Leases. The FASB has issued subsequent amendments to improve and clarify the implementation guidance of Topic 842. The new standard requires an entity to recognize leases on the balance sheet and to disclose key information about the entity's leasing arrangements. The Company adopted this standard as of January 1, 2019 using the modified retrospective transition approach, including certain practical expedients, for all leases existing as of January 1, 2019, the effective and initial application date. Prior period financial statements were not recast under the new guidance. The Company elected to apply practical expedients, to not separate non-lease components from lease components, and to not reassess lease classification, treatment of initial direct costs, or whether an existing or expired contract contains a lease. The Company also elected to use the short-term exemption for all class assets. The adoption of the new standard resulted in recognition of operating lease liabilities of approximately $3.0 million with corresponding right-of-use assets of approximately the same amount. There was no impact to retained earnings upon adoption. This standard had a material impact on the Consolidated Balance Sheets and did not have a material impact on the Company’s Consolidated Statements of Operations and Consolidated Statements of Cash Flows.

See Note 9, Leases, for further information.

ASU No. 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU No. 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods. The Company does not expect the adoption of the new guidance under the standard to materially affect its financial position or results of operations.

ASU No. 2017-08

In March 2017, the FASB issued ASU No. 2017-08, Receivables–Nonrefundable Fees and Other Costs (Subtopic 310-20). Under the ASU, entities must amortize to the earliest call date the premium on certain purchased callable debt securities. The ASU does not require any accounting change for debt securities held at a discount. The guidance calls for a modified retrospective transition approach under which a cumulative-effect adjustment will be made to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this update did not have a material impact on the Company’s consolidated financial statements or disclosures.

ASU No. 2018-02

In February 2018, the FASB issued ASU No. 2018-02, Income Statement–Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted by the U.S. federal government on December 22, 2017 (the “2017 Tax Act”). Consequently, the amendments eliminate the stranded tax effects resulting from the 2017 Tax Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The adoption of this update did not have a material impact on the Company’s consolidated financial statements or disclosures.

ASU No. 2018-15

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which provides new guidance on the accounting for implementation, set-up, and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an internal-use software license arrangement. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This ASU can be adopted prospectively to eligible costs incurred on or after the date of adoption or retrospectively. The Company does not expect the adoption of the new guidance under the standard to materially affect its financial position or results of operations.

ASU No. 2019-12

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users. The amendment in this update simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. This amendment is effective for public business entities beginning after December 15, 2020 with early adoption permitted. The Company has decided not to early adopt the amendments. The Company is currently evaluating the amendment and has not yet determined the impact on its consolidated financial statements.

Marketable Securities

12 Months Ended

Dec. 31, 2019

Investments Debt And Equity Securities [Abstract]

Marketable Securities

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following:

	December 31, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	4,700		$	—	$	—		$	4,700
Corporate debt securities		17,962			43		(2	)		18,003
Less: Cash equivalents		(6,399	)		—		—			(6,399	)
Total short-term marketable securities		16,263			43		(2	)		16,304
Corporate debt securities		41,861			116		(30	)		41,947
Total long-term marketable securities		41,861			116		(30	)		41,947
Total marketable securities	$	58,124		$	159	$	(32	)	$	58,251

	December 31, 2018
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	2,692		$	—	$	—		$	2,692
United States Treasury		990			—		—			990
U.S. government agency securities		790			—		—			790
Corporate debt securities		22,613			1		(96	)		22,518
Less: Cash equivalents		(2,692	)		—		—			(2,692	)
Total short-term marketable securities		24,393			1		(96	)		24,298
Corporate debt securities		6,383			11		(8	)		6,386
Total long-term marketable securities		6,383			11		(8	)		6,386
Total marketable securities	$	30,776		$	12	$	(104	)	$	30,684

Management determined that the gross unrealized losses of $32,000 on the Company’s marketable securities as of December 31, 2019 were temporary in nature. Gross unrealized losses on the Company’s marketable securities were $104,000 as of December 31, 2018. The Company currently does not intend to sell these securities prior to maturity and does not consider these investments to be other-than-temporarily impaired as of December 31, 2019.

Fair Value Measurements

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1:	Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.
Level 2:	Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3:	Inputs are unobservable inputs for the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	59,950	$	—	$	59,950	$	—
Money market accounts		4,700		4,700		—		—
Total marketable securities and cash equivalents	$	64,650	$	4,700	$	59,950	$	—

	December 31, 2018
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	28,904	$	—	$	28,904	$	—
United States Treasury		990		—		990		—
U.S. government agency securities		790		—		790		—
Money market accounts		2,692		2,692		—		—
Total marketable securities and cash equivalents	$	33,376	$	2,692	$	30,684	$	—

The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of United States Treasury, U.S. government agency securities, and corporate debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of December 31, 2019 and 2018, the Company had no investments that were measured using unobservable (Level 3) inputs.

There were no transfers between fair value measurement levels during the years ended December 31, 2019 and 2018.

Gross unrealized gains or losses for cash equivalents and marketable securities as of December 31, 2019 were not material. As of December 31, 2019, unrealized losses for securities in an unrealized loss position for more than 12 months were zero. During the years ended December 31, 2019 and 2018, the Company did not recognize other-than-temporary impairment losses related to its marketable securities.

Fixed Assets

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Fixed Assets

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:

		December 31,
	Useful Lives	2019			2018
		(in thousands)
Computer hardware	3 Years	$	1,705		$	1,579
Computer software	3 Years		541			495
Medical lab equipment	5 Years		10,493			8,136
Furniture and fixtures	5 Years		235			233
Leasehold improvements	Shorter of lease term or estimated useful life		876			802
Assets not yet placed in service			114			1,087
Total			13,964			12,332
Less: Accumulated depreciation			(7,990	)		(5,886	)
Property and equipment, net		$	5,974		$	6,446

Depreciation expense on fixed assets totaled $2.1 million and $2.2 million for the years ended December 31, 2019 and 2018, respectively.

Other Current Assets

12 Months Ended

Dec. 31, 2019

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

Note 6. Other Current Assets

Other current assets consisted of the following:

	December 31,
	2019		2018
	(in thousands)
Reagents	$	277	$	314
Contract assets		150		150
Prepaid expenses		1,288		556
Prepaid income taxes		46		1,251
Marketable securities interest receivable		478		220
Other receivable		16		70
Total	$	2,255	$	2,561

Reagents are used for DNA sequencing applications in the Company’s DNA sequencing equipment.

Reporting Segment and Geographic Information

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Reporting Segment and Geographic Information

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of December 31, 2019 with an insignificant amount located in Canada. All long-lived assets were located in the United States as of December 31, 2018. Revenue by region for the years ended December 31, 2019 and 2018 were as follows:

	Year Ended December 31,
	2019		2018
	(in thousands)
Revenue:
United States	$	25,014	$	12,579
Foreign:
Canada		2,245		3,984
Other Countries		5,269		4,788
Total	$	32,528	$	21,351

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8. Commitments and Contingencies

Operating Leases

See Note 9, Leases, for further information.

Gene Biotech

See Note 15 for a description of the Company’s commitments related to its joint venture, FF Gene Biotech (as defined in Note 15).

Purchase Obligations

As of December 31, 2019, the Company had non-cancelable purchase obligations of $2.9 million for reagents and other supplies, of which, $1.5 million is payable within twelve months, and $1.4 million is payable within the next twenty-four months.

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases

Note 9. Leases

The Company has various non-cancelable operating leases with varying terms through August 2023 primarily for office space. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. The Company does not have any finance leases or leases with variable lease payments.

The determination of whether an arrangement contains a lease is made at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset.

The Company’s headquarters is located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), accredited by the College of American Pathologists (“CAP”) and licensed by the State of California Department of Public Health. Additional offices are located in El Monte, California and Atlanta, Georgia and are used for certain research and development, customer service, report generation and other administrative functions.

Rent expense, including sublease consideration, was approximately $548,000 and $418,000 for the years ended December 31, 2019 and 2018, respectively.

The Company adopted new accounting standard ASC 842, Leases, on January 1, 2019. Upon adoption, the Company recorded ROU assets of $3.0 million and short-term and long-term lease liabilities of $384,000 and $2.6 million, respectively. The difference between the ROU asset and liability is due to the existing balance of deferred rent at the date of adoption. There was no impact to retained earnings upon adoption. The Company terminated the lease in Georgia on August 31, 2019 and entered into a new lease on September 1, 2019. Upon entering the new lease, the Company recorded ROU assets of $110,000 and short term and long-term lease liabilities of $23,000 and $87,000, respectively.

As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the discount rate used to calculate present value lease payment. The Company determined its incremental borrowing rate based on inquiries with its bank. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations. Lease expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company’s leases do not contain variable lease payments. The Company does not have any short-term leases and thus has excluded short-term costs from the table below. Other than the new lease in Georgia, the Company did not enter into any new leases during the year ended December 31, 2019.

The following was operating lease expense:


	Year Ended December 31, 2019
	(in thousands)
Operating lease cost	$	587

Supplemental cash flow information related to leases was the following:


	Year Ended December 31, 2019
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	535
Noncash lease expense	$	413
Right-of-assets obtained in exchange for new operating lease liabilities	$	110

Supplemental information related to leases was the following:

	December 31, 2019
Weighted average remaining lease term - operating leases	5.6 years
Weighted average discount rate - operating leases		6.25	%

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2020	$	575
2021		591
2022		597
2023		567
2024		330
Thereafter		532
Total lease payments		3,192
Less imputed interest		(516	)
Total	$	2,676

Supplemental Information for Comparative Periods

As of December 31, 2018, prior to the adoption of Topic 842, future minimum payments under non-cancelable operating leases are as follows:

	Operating Leases
	(in thousands)
Year Ending December 31,
2019	$	560
2020		559
2021		550
2022		558
2023		567
Thereafter		862
Total minimum payments	$	3,656

Equity-Based Compensation

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

Note 10. Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Consolidated Statements of Operations as follows:

	Year Ended December 31,
	2019		2018
	(in thousands)
Cost of revenue	$	676	$	523
Research and development		1,024		732
Selling and marketing		845		460
General and administrative		664		589
Total	$	3,209	$	2,304

Award Activity

Option Awards

The following table summarizes activity for options to acquire shares of the Company’s common stock in the years ended December 31, 2019 and 2018:

	Number of Shares Subject to Options (in thousands)			Weighted- Average Exercise Price		Weighted- Average Grant Date Fair Value		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value (in thousands) (1)
Balance at December 31, 2017		465		$	0.84				8.0	$	1,785
Granted		10		$	3.93	$	2.92
Exercised		(40	)	$	0.38	$	5.80
Canceled		(18	)	$	8.19	$	8.47
Balance at December 31, 2018		417		$	0.64				7.1	$	1,116
Granted		30		$	6.98	$	4.58
Exercised		(100	)	$	0.38	$	5.36
Canceled		(6	)	$	0.38	$	7.10
Balance at December 31, 2019		341		$	1.27				6.4	$	3,960
Exercisable as of December 31, 2019		284		$	0.64				6.0	$	3,482

(1)	Aggregate intrinsic value is calculated as the difference between (i) the exercise price of options that, as of the applicable date, have an exercise price in excess of the fair value of the Company’s common stock, and (ii) the fair value of the Company’s common stock as of the applicable date.

The total fair value of options that vested during the years ended December 31, 2019 and 2018 was $549,000 and $645,000, respectively. As of December 31, 2019, the remaining unrecognized compensation expense related to all outstanding option awards was $146,000 and is expected to be recognized over a weighted-average period of 0.5 year.

RSU Awards

RSUs are awards that entitle the holder to receive shares of the Company’s common stock upon satisfaction of vesting conditions. Each RSU represents the contingent right to receive one share of the Company’s common stock upon vesting and settlement.

The following table summarizes activity for RSUs relating to shares of the Company’s common stock in the years ended December 31, 2019 and 2018:

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value
Balance at December 31, 2017		937		$	7.39
Granted		554		$	4.39
Vested and settled		(285	)	$	7.78
Forfeited		(120	)	$	5.77
Balance at December 31, 2018		1,086		$	5.94
Granted		982		$	7.00
Vested and settled		(434	)	$	6.39
Forfeited		(123	)	$	5.38
Balance at December 31, 2019		1,511		$	6.54

The RSU awards granted in the years ended December 31, 2019 and 2018 will result in aggregate equity-based compensation expense of $6.9 million and $2.4 million, respectively, in each case to be recognized over four years from the grant date of each award granted in the period. As of December 31, 2019, the remaining unrecognized compensation expense related to all outstanding RSU awards was $8.7 million and is expected to be recognized over a weighted-average period of 2.9 years. As of December 31, 2018, the remaining unrecognized compensation expense related to all outstanding RSU awards was $5.6 million and is expected to be recognized over a weighted-average period of 2.9 years.

Fair Value Assumptions for Option Awards

The Company uses the Black-Scholes option-pricing model to measure the fair value of option awards. The Black-Scholes option-pricing model requires the input of various assumptions, each of which is subjective and requires significant judgment. These assumptions include the following:

•

Expected Term. The expected term represents the period that the Company’s equity-based awards are expected to be outstanding. The Company determines the expected term assumption based on the vesting terms, exercise terms and contractual terms of the options.

•

Risk-Free Interest Rate. The Company determines the risk-free interest rate by using the equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.

•

Dividend Yield. The assumed dividend yield is based on the Company’s expectation that it will not pay dividends in the foreseeable future, which is consistent with its history of not paying dividends.

•

Expected Volatility. The Company calculates expected volatility based on historical volatility data of its stock that is publicly traded.

•

Forfeiture Rate. The Company accounts for forfeitures as they occur.

Awards to Employees

The table below sets forth the weighted-average assumptions used in the Black-Scholes option-pricing model to estimate the fair value of options to acquire shares of the Company’s common stock granted to employees during the year ended December 31, 2019 and 2018.

	Year Ended December 31,
	2019			2018
Expected term (in years)		6.1			6.1
Risk-free interest rates		1.8	%		2.8	%
Dividend yield		—			—
Expected volatility		73.6	%		87.4	%

Determination of Fair Value on Grant Dates

The fair value of the shares of the Company’s common stock underlying option and RSU awards is determined by the Company’s board of directors or the compensation committee thereof based on the closing sales price of the Company’s common stock on the date of grant as reported by the Nasdaq Global Market.

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 11. Income Taxes

Provision for income taxes consists of U.S. federal and state income taxes. A deferred tax liability is recognized for all taxable temporary differences, and a deferred tax asset is recognized for all deductible temporary differences, operating losses and tax credit carryforwards. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

As of December 31, 2019 and 2018 the Company has incurred net taxable losses, and accordingly, a current provision for income taxes has only been recorded for nominal federal and state taxes. This amount differs from the amount computed by applying the U.S. federal income tax rate of 21.0% to pretax loss due primarily to the provision of a valuation allowance to the extent of the Company’s net deferred tax asset.

The following table summarizes income (loss) before income taxes and equity loss in investee:

	Year Ended December 31,
	2019			2018
	(in thousands)
U.S. income (loss) before income taxes and equity loss in investee	$	679		$	(4,602	)
Foreign income (loss) before income taxes and equity loss in investee		(270	)		(34	)
Income (loss) before income taxes and equity loss in investee	$	409		$	(4,636	)

Income tax expense (benefit) consisted of the following:

	Year Ended December 31,
	2019			2018
	(in thousands)
Current:
Federal	$	5		$	—
State		38			—
Total Current		43			—
Deferred:
Federal		(249	)		(987	)
State		(280	)		(308	)
Change in valuation allowance		529			1,331
Total Deferred		—			36
Total income tax expense (benefit)	$	43		$	36

Reconciliation of the difference between the federal statutory income tax rate and the effective income tax rate is as follows:

	Year Ended December 31,
	2019			2018
Tax provision at federal statutory rate		21.00	%		21.00	%
State taxes		-46.76	%		4.37	%
Foreign tax rate differential		13.83	%	—
Stock based compensation		-53.53	%		-4.08	%
Return to provision		-57.11	%		2.31	%
Meals and entertainment		3.87	%		-0.13	%
Other		0.01	%		-0.22	%
Change in valuation allowance		129.22	%		-23.90	%
Tax provision		10.53	%		-0.65	%

The following table summarizes the elements of the deferred tax assets (liabilities):

	Year Ended December 31,
	2019			2018
	(in thousands)
Deferred tax assets
Accrued vacation and other accrued expenses	$	97		$	118
Provision for bad debts		180			136
Net operating losses		445			699
Stock based compensation		609			579
Unrealized loss on investments	—				21
State income taxes		8			9
Foreign		545			343
Credits		680			261
Lease liability		643			—
Gross deferred tax assets		3,207			2,166
Less: Valuation allowance		(2,125	)		(1,448	)
Net deferred tax assets		1,082			718
Deferred tax liabilities
Depreciation		419			644
Right of use asset		633			—
Other		30			74
Total deferred tax liabilities		1,082			718
Net deferred tax assets (liabilities)	$	—		$	—

As of December 31, 2019, the Company has estimated federal and state net operating loss (“NOL”) carryforwards of $1.6 million and $1.9 million for federal and state income tax purposes, respectively. The Company’s federal NOL of $1.6 million does not expire. The Company’s state NOLs are scheduled to expire from 2022 through 2039. Past ownership changes and other equity transactions may have triggered Section 382 and 383 provisions of the Internal Revenue Code, resulting in certain annual limitations on the utilization of existing federal and state net operating losses and credits. Such provisions may limit the potential future tax benefit to be realized by the Company from its accumulated net operating losses and credits.

FASB ASC 740 requires that deferred income tax assets be reduced by a valuation allowance if it is more likely than not that some or all of the deferred income tax assets will not be realized. The Company has evaluated the realizability of its deferred tax assets and has concluded that it is more likely than not that the Company may not realize the benefit of its deferred tax assets, primarily as a result of operating losses in recent years and, accordingly, has provided a full valuation allowance of $2.1 million and $1.4 million at December 31, 2019 and 2018, respectively. The increase in the valuation allowance of $677,000 for the year ended December 31, 2019 was primarily due to net operating losses, depreciation, research and development credits, equity-based compensation, our foreign joint venture investment, and the lease liability and related right of use asset.

During 2019 and 2018 the Company recorded a deferred tax asset related to its equity method investment in FF Gene Biotech. When realized, the asset will generate a capital loss which may only be used to offset capital gain income. The Company does not currently have any capital gain income and has therefore recorded a full valuation allowance against this asset.

Uncertain Tax Positions

The Company is subject to income taxation by the United States government and certain states in which the Company's activities give rise to an income tax filing requirement. The Company does not have income tax filing requirements in any foreign jurisdiction. As of December 31, 2019, there were no pending tax audits in any jurisdiction. The tax returns are subject to statutes of limitations that vary by jurisdiction. At December 31, 2019, the Company remains subject to income tax examinations in the U.S. and various states for tax years 2016 through 2019.

The Company had no accrual for interest or penalties at December 31, 2019 or 2018, and has not recognized interest or penalties during the years ended December 31, 2019 and 2018.

While the Company believes it has adequately provided for all tax positions, amounts asserted by taxing authorities could differ from the Company's accrued positions. Accordingly, additional provisions on federal, state and foreign tax-related matters could be recorded in future periods as revised estimates are settled or otherwise resolved.

Loss Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Loss per Share

Note 12. Loss per Share

The following is a reconciliation of the basic and diluted loss per share computations:

	Year Ended December 31,
	2019			2018
	(in thousands, except per share data)
Net loss	$	(411	)	$	(5,607	)
Weighted-average common shares - outstanding, basic		18,709			17,978
Weighted-average common shares - outstanding, diluted		18,709			17,978
Net loss per common share, basic	$	(0.02	)	$	(0.31	)
Net loss per common share, diluted	$	(0.02	)	$	(0.31	)

The following securities have been excluded from the calculation of diluted loss per share for all periods presented because their effect would have been anti-dilutive:

	Year Ended December 31,
	2019		2018
	(in thousands)
Options		36		413
RSUs		161		857

The anti-dilutive shares described above were calculated using the treasury stock method. During the years ended December 31, 2019 and 2018, the Company had outstanding options and RSUs that were excluded from the weighted-average share calculation for continuing operations due to the Company’s net loss positions.

Retirement Plans

12 Months Ended

Dec. 31, 2019

Compensation And Retirement Disclosure [Abstract]

Retirement Plans

Note 13. Retirement Plans

The Company offers a 401(k) retirement savings plan (the “401(k) Plan”) for its employees, including its executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code of 1986, as amended, allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) Plan. The Company matches contributions to the 401(k) Plan based on the amount of salary deferral contributions the participant makes to the 401(k) Plan. The Company will match up to 3% of an employee’s compensation that the employee contributes to his or her 401(k) Plan account. Total Company matching contributions to the 401(k) Plan were $237,000 and $176,000 in the years ended December 31, 2019 and 2018, respectively.

Related Party

12 Months Ended

Dec. 31, 2019

Related Party

Note 14. Related Party

Dr. Yun Yen, who is a member of the Company’s Board of Directors and a stockholder, serves as the President and Chairman of the Board for the Sino-American Cancer Foundation (the “Foundation”) and served as the President for the Taipei Medical University (the “University”), from August 1, 2011 through July 31, 2016 and currently serves as a Chair Professor for the University.

From time to time, the Company performs research testing services, on an arms-length basis, for the Foundation. The Company recognized an insignificant amount and zero during the years ended December 31, 2019 and 2018, respectively, as consideration for such services. Additionally, the Company subleases certain of its headquarters facilities to the Foundation. The Company recognized $16,000 and $33,000 in the years ended December 31, 2019 and 2018, respectively, as consideration for such sublease. As of December 31, 2019 and 2018, an insignificant amount and zero, respectively, was owed to the Company by the Foundation in connection with these relationships.

From time to time, the Company performs genetic sequencing services, on an arms-length basis, for the University. The Company recognized $53,000 and $66,000 in the years ended December 31, 2019 and 2018, respectively, as consideration for such services. As of December 31, 2019 and 2018, $39,000 and $51,000, respectively, was owed to the Company by the University in connection with this relationship.

As more fully described in Note 15, in April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into a cooperation agreement (the “JV Agreement”) with Xilong Scientific Co., Ltd. (“Xilong Scientific”) and Fuzhou Jinqiang Investment Partnership (LP) (“FJIP”) to form a joint venture under the laws of the PRC called Fujian Fujun Gene Biotech Co., Ltd. (“FF Gene Biotech”). Xilong Scientific is an affiliate of Xi Long, which, as of December 31, 2019, owned 9% of the outstanding shares of the Company’s common stock, and FJIP is owned by key management of FF Gene Biotech, including Dr. Han Lin Gao, the Chief Scientific Officer and a large stockholder of the Company and the owner of approximately 25% of FJIP.

Fulgent Pharma utilizes space in the facility at which the Company’s laboratory and corporate headquarters are located. Since the completion of the Pharma Split-Off, Fulgent Pharma reimburses the Company, on an arms-length basis, for the portion of the rent the Company pays that is attributable to the space used by Fulgent Pharma, which amounts are not significant. As of December 31, 2019 and 2018, $26,000 and $22,000, respectively, was owed to the Company by Fulgent Pharma as a result of this arrangement, which is recorded in Other receivable in Other current assets in the accompanying Consolidated Balance Sheets.

Equity Method Investments

12 Months Ended

Dec. 31, 2019

Equity Method Investments And Joint Ventures [Abstract]

Equity Method Investments

Note 15. Equity Method Investments

In April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into the JV Agreement with Xilong Scientific and FJIP to form FF Gene Biotech, a joint venture formed under the laws of the PRC to offer genetic testing services to customers in the PRC. Pursuant to the terms of the JV Agreement, the Company has agreed to contribute to FF Gene Biotech genetic sequencing and other equipment with a total cost of 60,000,000 renminbi (“RMB”) over a five-year period for a 30% ownership interest in FF Gene Biotech, previously three-year per original agreement and amended in April 2019. Xilong Scientific has agreed to contribute to FF Gene Biotech 102,000,000 RMB over a five-year period for a 51% ownership interest in the FF Gene Biotech, previously three-year per original agreement and amended in April 2019. FJIP has agreed to contribute to FF Gene Biotech 19,000,000 RMB over a ten-year period for a 19% ownership interest in FF Gene Biotech, previously five-year per original agreement and amended in April 2019. The Company’s maximum exposure to fund losses of FF Gene Biotech as a result of its minority ownership of this entity is equal to its contribution obligation under the JV Agreement as described above. As of December 31, 2019, 39,300,000 RMB (or approximately $5.6 million U.S. dollars) remained to be contributed to FF Gene Biotech by the Company under the terms of the JV Agreement, and the Company has purchased and contributed equipment with an aggregate fair value of $3.1 million pursuant to its contribution commitment under the JV Agreement, of which, $137,000 and $510,000 were contributed in the year ended December 31, 2019 and 2018, respectively. The Company accounted for this contribution in accordance with ASC 845, Nonmonetary Transactions, and recorded an investment based on the fair value of the contributed equipment, which is the same as carryover basis.

The Company concluded FF Gene Biotech is a variable interest entity as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone does not have the power to direct the most significant activities of FF Gene Biotech and therefore is not the primary beneficiary of the entity. Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions.

The Company accounts for its 30% interest in FF Gene Biotech using the equity method of accounting. The Company recorded its proportionate share of the losses of FF Gene Biotech for the year ended December 31, 2019 and 2018 in the accompanying Consolidated Statements of Operations, and recorded its contribution during the period, net of its proportionate share in the accumulated losses of FF Gene Biotech, in the accompanying Consolidated Balance Sheet as of December 31, 2019 and 2018.

The Company entered into a license agreement with FF Gene Biotech, pursuant to which it granted FF Gene Biotech a license to use certain of the Company’s clinical molecular diagnostic gene detection technology and related software and proprietary reference library of genetic information, along with any improvements on this technology the Company may develop during the term of the license agreement. Under the license agreement, FF Gene Biotech paid to the Company, on a quarterly basis, certain royalties based on the revenues of FF Gene Biotech. The license agreement expired on December 31, 2018. The Company earned an insignificant amount of royalties under the license agreement for the year ended December 31, 2018. In 2019, FF Gene Biotech provided curation services, on an arms-length basis, for the Company, the cost of such services was insignificant for the year ended December 31, 2019.

The financial information of the subsidiary is consolidated in the summarized financial information for FF Gene Biotech disclosed below.

Equity method investments as of December 31, 2019 and 2018 consisted of the following:

	December 31,
	2019					2018
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)					(in thousands)
FF Gene Biotech	$	872		30	%	$	1,512		30	%
Total equity method investments	$	872		30	%	$	1,512		30	%

Summary Financial Information

Summary financial information for FF Gene Biotech is as follows:

	December 31,
	2019			2018
Consolidated Balance Sheet Data:	(in thousands)
Current assets	$	3,007		$	1,916
Non-current assets	$	4,457		$	4,068
Current liabilities	$	3,748		$	2,415
Non-current liabilities	$	889		$	—
Minority interest	$	(426	)	$	—
Stockholders' equity	$	3,253		$	3,569

	Year Ended December 31,
	2019			2018
Consolidated Statement of Operations Data:	(in thousands)
Net sales	$	4,055		$	1,254
Gross profit	$	1,354		$	67
Net loss	$	(3,009	)	$	(3,101	)

Share of loss from investments accounted for using the equity method	$	(777	)	$	(935	)

Equity Distribution Agreement

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Equity Distribution Agreement

Note 16. Equity Distribution Agreement

In August 2019, the Company entered into an Equity Distribution Agreement with Piper Jaffray & Co., as sales agent (“Piper”), pursuant to which the Company may offer and sell, from time to time through Piper, shares of its common stock having an aggregate offering price of up to $30.0 million. Piper is eligible to receive a commission of up to 3% of gross proceeds received by the Company for sales pursuant to the Equity Distribution Agreement. During the year ended December 31, 2019, the Company sold an aggregate of 104,390 shares of its common stock pursuant to the Equity Distribution Agreement at a weighted-average selling price of $12.14 per share, which resulted in $979,000 of net proceeds to the Company. Shares sold under the Equity Distribution Agreement are offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-233227) filed with the SEC on August 12, 2019 and declared effective on August 23, 2019, and a prospectus supplement and accompanying base prospectus filed with the Securities and Exchange Commission on August 30, 2019.

Underwriting Agreement

12 Months Ended

Dec. 31, 2019

Underwriting Agreement [Abstract]

Underwriting Agreement

Note 17. Underwriting Agreement

On November 13, 2019 we entered into a Purchase Agreement with Piper Jaffray & Co. as representative of the several underwriters, pursuant to which we sold 2,673,750 shares of our common stock at a price of $10.51875 per share, with a public offering price of $11.25 per share. We received net proceeds of approximately $27.6 million, after deducting underwriting discounts and commissions and offering expenses paid or payable by us of approximately $2.4 million. The shares issued and sold in the underwritten offering were sold pursuant to a shelf registration statement registered under the Securities Act on a registration statement on Form S-3 (File No. 333-233227), as amended, and a prospectus supplement and accompanying base prospectus filed with the Securities and Exchange Commission on November 13, 2019.

Selected Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Information (Unaudited)

Note 18. Selected Quarterly Financial Data (Unaudited)

The tables below set forth the Company’s quarterly Consolidated Statements of Operations data for the eight quarters ended December 31, 2019. In the opinion of management, this quarterly data has been prepared on the same basis as the accompanying consolidated financial statements and includes all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the results of operations for the periods presented. See Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the report in which these consolidated financial statements are included for descriptions of the effects of any extraordinary, unusual or infrequently occurring items recognized in any of the periods covered by this data. The results for any one quarter are not indicative of the results to be expected in the current period or any future period.

	Three Months Ended
	Dec. 31, 2019			Sept. 30, 2019			June 30, 2019			Mar. 31, 2019			Dec. 31, 2018			Sept. 30, 2018			June 30, 2018			Mar. 31, 2018
	(dollars in thousands, except per share data)
Statement of Operations Data:
Revenue	$	8,387		$	10,347		$	8,424		$	5,370		$	5,673		$	5,625		$	5,400		$	4,653
Cost of revenue		3,634			3,885			3,620			2,968			2,769			2,612			2,544			2,772
Gross profit		4,753			6,462			4,804			2,402			2,904			3,013			2,856			1,881
Operating expenses:
Research and development		1,795			1,744			1,574			1,424			1,426			1,438			1,212			1,458
Selling and marketing		1,635			1,687			1,304			1,272			1,128			1,115			1,279			1,130
General and administrative		1,732			1,522			1,631			1,529			1,379			1,306			1,366			1,487
Total operating expenses		5,162			4,953			4,509			4,225			3,933			3,859			3,857			4,075
Operating income (loss)		(409	)		1,509			295			(1,823	)		(1,029	)		(846	)		(1,001	)		(2,194	)
Interest and other income, net		249			189			192			207			98			143			98			95
Income (loss) before income taxes and equity loss in investee		(160	)		1,698			487			(1,616	)		(931	)		(703	)		(903	)		(2,099	)
Provision for (benefit from) income taxes		(38	)		61			7			13			888			(318	)		(100	)		(434	)
Income (loss) before equity loss in investee		(122	)		1,637			480			(1,629	)		(1,819	)		(385	)		(803	)		(1,665	)
Equity loss in investee		(174	)		(175	)		(149	)		(279	)		(234	)		(210	)		(246	)		(245	)
Net income (loss)	$	(296	)	$	1,462		$	331		$	(1,908	)	$	(2,053	)	$	(595	)	$	(1,049	)	$	(1,910	)

Net income (loss) per common share:
Basic	$	(0.01	)	$	0.08		$	0.02		$	(0.10	)	$	(0.11	)	$	(0.03	)	$	(0.06	)	$	(0.11	)
Diluted	$	(0.01	)	$	0.08		$	0.02		$	(0.10	)	$	(0.11	)	$	(0.03	)	$	(0.06	)	$	(0.11	)

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Cash and Cash Equivalents

Accounts Receivable and Allowance for Doubtful Accounts

A roll-forward of the activity in the Company’s allowance for doubtful accounts is as follows:

	December 31,
	2019			2018
	(in thousands)
Allowance for doubtful accounts at beginning of year	$	590		$	287
Bad debt expense		189			309
Deductions		(28	)		(6	)
Allowance for doubtful accounts at end of year	$	751		$	590

Marketable Securities

Fair Value of Financial Instruments

Concentrations of Credit Risk, Customers and Suppliers

Revenue from the U.S. government was less than 10% of total revenue in each of the years ended December 31, 2019 and 2018.

Equity Method Investments

Leases

Fixed Assets

Software for Internal Use

Impairment of Long-Lived Assets

Reporting Segment and Geographic Information

Revenue Recognition

Performance Obligations

Genetic Testing Services

Clinical – Institutional and Patient Direct Pay

Clinical – Insurance

Significant Judgments and Contract Estimates

Genetic Testing Services

Disaggregation of Revenue

	Year Ended December 31,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	31,284	$	19,980
Patient		539		547
Insurance		705		824
Total Revenue	$	32,528	$	21,351

There was no material variable consideration recognized in the current period that relates to performance obligations that were completed in the prior period.

Contract Balances

Reclassifications

Transaction Price Allocated to Future Performance Obligations

Contract Liabilities

Overhead Expenses

Cost of Revenue

Research and Development Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Income Taxes

Equity-Based Compensation

Foreign Currency Translation and Foreign Currency Transactions

Comprehensive Loss

Basic and Diluted Net Loss per Share

Emerging Growth Company

Recent Accounting Pronouncements

ASU No. 2016-01

ASU No. 2016-02

See Note 9, Leases, for further information.

ASU No. 2016-13

ASU No. 2017-08

ASU No. 2018-02

ASU No. 2018-15

ASU No. 2019-12

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Roll-Forward of Activity in Allowance for Doubtful Accounts

A roll-forward of the activity in the Company’s allowance for doubtful accounts is as follows:

	December 31,
	2019			2018
	(in thousands)
Allowance for doubtful accounts at beginning of year	$	590		$	287
Bad debt expense		189			309
Deductions		(28	)		(6	)
Allowance for doubtful accounts at end of year	$	751		$	590

Accounting Standards Update 2014-09

Summary of Revenue from Contracts with Customers by Payor Type

The following table summarizes revenue from contracts with customers by payor type for the years ended December 31, 2019 and 2018.

	Year Ended December 31,
	2019		2018
	(in thousands)
Genetic Testing Services by payor
Institutional	$	31,284	$	19,980
Patient		539		547
Insurance		705		824
Total Revenue	$	32,528	$	21,351

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2019

Investments Debt And Equity Securities [Abstract]

Summary of Marketable Securities

The Company’s marketable securities consisted of the following:

	December 31, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	4,700		$	—	$	—		$	4,700
Corporate debt securities		17,962			43		(2	)		18,003
Less: Cash equivalents		(6,399	)		—		—			(6,399	)
Total short-term marketable securities		16,263			43		(2	)		16,304
Corporate debt securities		41,861			116		(30	)		41,947
Total long-term marketable securities		41,861			116		(30	)		41,947
Total marketable securities	$	58,124		$	159	$	(32	)	$	58,251

	December 31, 2018
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	2,692		$	—	$	—		$	2,692
United States Treasury		990			—		—			990
U.S. government agency securities		790			—		—			790
Corporate debt securities		22,613			1		(96	)		22,518
Less: Cash equivalents		(2,692	)		—		—			(2,692	)
Total short-term marketable securities		24,393			1		(96	)		24,298
Corporate debt securities		6,383			11		(8	)		6,386
Total long-term marketable securities		6,383			11		(8	)		6,386
Total marketable securities	$	30,776		$	12	$	(104	)	$	30,684

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	59,950	$	—	$	59,950	$	—
Money market accounts		4,700		4,700		—		—
Total marketable securities and cash equivalents	$	64,650	$	4,700	$	59,950	$	—

	December 31, 2018
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	28,904	$	—	$	28,904	$	—
United States Treasury		990		—		990		—
U.S. government agency securities		790		—		790		—
Money market accounts		2,692		2,692		—		—
Total marketable securities and cash equivalents	$	33,376	$	2,692	$	30,684	$	—

Fixed Assets (Tables)

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Major Classes of Fixed Assets

Major classes of fixed assets consisted of the following:

		December 31,
	Useful Lives	2019			2018
		(in thousands)
Computer hardware	3 Years	$	1,705		$	1,579
Computer software	3 Years		541			495
Medical lab equipment	5 Years		10,493			8,136
Furniture and fixtures	5 Years		235			233
Leasehold improvements	Shorter of lease term or estimated useful life		876			802
Assets not yet placed in service			114			1,087
Total			13,964			12,332
Less: Accumulated depreciation			(7,990	)		(5,886	)
Property and equipment, net		$	5,974		$	6,446

Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2019

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following:

	December 31,
	2019		2018
	(in thousands)
Reagents	$	277	$	314
Contract assets		150		150
Prepaid expenses		1,288		556
Prepaid income taxes		46		1,251
Marketable securities interest receivable		478		220
Other receivable		16		70
Total	$	2,255	$	2,561

Reporting Segment and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Summary of Revenue by Geographic Region

Revenue by region for the years ended December 31, 2019 and 2018 were as follows:

	Year Ended December 31,
	2019		2018
	(in thousands)
Revenue:
United States	$	25,014	$	12,579
Foreign:
Canada		2,245		3,984
Other Countries		5,269		4,788
Total	$	32,528	$	21,351

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Schedule of Operating Lease Expense

The following was operating lease expense:


	Year Ended December 31, 2019
	(in thousands)
Operating lease cost	$	587

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was the following:


	Year Ended December 31, 2019
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	535
Noncash lease expense	$	413
Right-of-assets obtained in exchange for new operating lease liabilities	$	110

Schedule Of Supplemental Information Related To Leases

Supplemental information related to leases was the following:

	December 31, 2019
Weighted average remaining lease term - operating leases	5.6 years
Weighted average discount rate - operating leases		6.25	%

Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2020	$	575
2021		591
2022		597
2023		567
2024		330
Thereafter		532
Total lease payments		3,192
Less imputed interest		(516	)
Total	$	2,676

Schedule of Future Minimum Payments for Noncancelable Operating Leases

As of December 31, 2018, prior to the adoption of Topic 842, future minimum payments under non-cancelable operating leases are as follows:

	Operating Leases
	(in thousands)
Year Ending December 31,
2019	$	560
2020		559
2021		550
2022		558
2023		567
Thereafter		862
Total minimum payments	$	3,656

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Consolidated Statements of Operations as follows:

	Year Ended December 31,
	2019		2018
	(in thousands)
Cost of revenue	$	676	$	523
Research and development		1,024		732
Selling and marketing		845		460
General and administrative		664		589
Total	$	3,209	$	2,304

Summary of Activity for Options to Acquire Common Shares

The following table summarizes activity for options to acquire shares of the Company’s common stock in the years ended December 31, 2019 and 2018:

	Number of Shares Subject to Options (in thousands)			Weighted- Average Exercise Price		Weighted- Average Grant Date Fair Value		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value (in thousands) (1)
Balance at December 31, 2017		465		$	0.84				8.0	$	1,785
Granted		10		$	3.93	$	2.92
Exercised		(40	)	$	0.38	$	5.80
Canceled		(18	)	$	8.19	$	8.47
Balance at December 31, 2018		417		$	0.64				7.1	$	1,116
Granted		30		$	6.98	$	4.58
Exercised		(100	)	$	0.38	$	5.36
Canceled		(6	)	$	0.38	$	7.10
Balance at December 31, 2019		341		$	1.27				6.4	$	3,960
Exercisable as of December 31, 2019		284		$	0.64				6.0	$	3,482

(1)	Aggregate intrinsic value is calculated as the difference between (i) the exercise price of options that, as of the applicable date, have an exercise price in excess of the fair value of the Company’s common stock, and (ii) the fair value of the Company’s common stock as of the applicable date.

Summary of Activity for RSUs Relating to Shares of Company's Common Stock

The following table summarizes activity for RSUs relating to shares of the Company’s common stock in the years ended December 31, 2019 and 2018:

	Number of Shares (in thousands)			Weighted-Average Grant Date Fair Value
Balance at December 31, 2017		937		$	7.39
Granted		554		$	4.39
Vested and settled		(285	)	$	7.78
Forfeited		(120	)	$	5.77
Balance at December 31, 2018		1,086		$	5.94
Granted		982		$	7.00
Vested and settled		(434	)	$	6.39
Forfeited		(123	)	$	5.38
Balance at December 31, 2019		1,511		$	6.54

Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Shares of Company's Common Stock

	Year Ended December 31,
	2019			2018
Expected term (in years)		6.1			6.1
Risk-free interest rates		1.8	%		2.8	%
Dividend yield		—			—
Expected volatility		73.6	%		87.4	%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Summary of Income (Loss) Before Income Taxes and Equity Loss in Investee

The following table summarizes income (loss) before income taxes and equity loss in investee:

	Year Ended December 31,
	2019			2018
	(in thousands)
U.S. income (loss) before income taxes and equity loss in investee	$	679		$	(4,602	)
Foreign income (loss) before income taxes and equity loss in investee		(270	)		(34	)
Income (loss) before income taxes and equity loss in investee	$	409		$	(4,636	)

Income Tax Expense (Benefit)

Income tax expense (benefit) consisted of the following:

	Year Ended December 31,
	2019			2018
	(in thousands)
Current:
Federal	$	5		$	—
State		38			—
Total Current		43			—
Deferred:
Federal		(249	)		(987	)
State		(280	)		(308	)
Change in valuation allowance		529			1,331
Total Deferred		—			36
Total income tax expense (benefit)	$	43		$	36

Reconciliation of Difference between Federal Statutory Income Tax Rate and Effective Income Tax Rate

Reconciliation of the difference between the federal statutory income tax rate and the effective income tax rate is as follows:

	Year Ended December 31,
	2019			2018
Tax provision at federal statutory rate		21.00	%		21.00	%
State taxes		-46.76	%		4.37	%
Foreign tax rate differential		13.83	%	—
Stock based compensation		-53.53	%		-4.08	%
Return to provision		-57.11	%		2.31	%
Meals and entertainment		3.87	%		-0.13	%
Other		0.01	%		-0.22	%
Change in valuation allowance		129.22	%		-23.90	%
Tax provision		10.53	%		-0.65	%

Summary of Elements of Deferred Tax Assets (Liabilities)

The following table summarizes the elements of the deferred tax assets (liabilities):

	Year Ended December 31,
	2019			2018
	(in thousands)
Deferred tax assets
Accrued vacation and other accrued expenses	$	97		$	118
Provision for bad debts		180			136
Net operating losses		445			699
Stock based compensation		609			579
Unrealized loss on investments	—				21
State income taxes		8			9
Foreign		545			343
Credits		680			261
Lease liability		643			—
Gross deferred tax assets		3,207			2,166
Less: Valuation allowance		(2,125	)		(1,448	)
Net deferred tax assets		1,082			718
Deferred tax liabilities
Depreciation		419			644
Right of use asset		633			—
Other		30			74
Total deferred tax liabilities		1,082			718
Net deferred tax assets (liabilities)	$	—		$	—

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Reconciliation of Basic and Diluted Loss Per Share Computations

The following is a reconciliation of the basic and diluted loss per share computations:

	Year Ended December 31,
	2019			2018
	(in thousands, except per share data)
Net loss	$	(411	)	$	(5,607	)
Weighted-average common shares - outstanding, basic		18,709			17,978
Weighted-average common shares - outstanding, diluted		18,709			17,978
Net loss per common share, basic	$	(0.02	)	$	(0.31	)
Net loss per common share, diluted	$	(0.02	)	$	(0.31	)

Anti-dilutive Securities Excluded from Calculation of Diluted Loss Per Share

The following securities have been excluded from the calculation of diluted loss per share for all periods presented because their effect would have been anti-dilutive:

	Year Ended December 31,
	2019		2018
	(in thousands)
Options		36		413
RSUs		161		857

Equity Method Investments (Tables)

12 Months Ended

Dec. 31, 2019

Equity Method Investments And Joint Ventures [Abstract]

Schedule of Equity Method Investments

Equity method investments as of December 31, 2019 and 2018 consisted of the following:

	December 31,
	2019					2018
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)					(in thousands)
FF Gene Biotech	$	872		30	%	$	1,512		30	%
Total equity method investments	$	872		30	%	$	1,512		30	%

Summary of Financial Information for Equity Method Investees

Summary financial information for FF Gene Biotech is as follows:

	December 31,
	2019			2018
Consolidated Balance Sheet Data:	(in thousands)
Current assets	$	3,007		$	1,916
Non-current assets	$	4,457		$	4,068
Current liabilities	$	3,748		$	2,415
Non-current liabilities	$	889		$	—
Minority interest	$	(426	)	$	—
Stockholders' equity	$	3,253		$	3,569

	Year Ended December 31,
	2019			2018
Consolidated Statement of Operations Data:	(in thousands)
Net sales	$	4,055		$	1,254
Gross profit	$	1,354		$	67
Net loss	$	(3,009	)	$	(3,101	)

Share of loss from investments accounted for using the equity method	$	(777	)	$	(935	)

Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Data

The tables below set forth the Company’s quarterly Consolidated Statements of Operations data for the eight quarters ended December 31, 2019.

	Three Months Ended
	Dec. 31, 2019			Sept. 30, 2019			June 30, 2019			Mar. 31, 2019			Dec. 31, 2018			Sept. 30, 2018			June 30, 2018			Mar. 31, 2018
	(dollars in thousands, except per share data)
Statement of Operations Data:
Revenue	$	8,387		$	10,347		$	8,424		$	5,370		$	5,673		$	5,625		$	5,400		$	4,653
Cost of revenue		3,634			3,885			3,620			2,968			2,769			2,612			2,544			2,772
Gross profit		4,753			6,462			4,804			2,402			2,904			3,013			2,856			1,881
Operating expenses:
Research and development		1,795			1,744			1,574			1,424			1,426			1,438			1,212			1,458
Selling and marketing		1,635			1,687			1,304			1,272			1,128			1,115			1,279			1,130
General and administrative		1,732			1,522			1,631			1,529			1,379			1,306			1,366			1,487
Total operating expenses		5,162			4,953			4,509			4,225			3,933			3,859			3,857			4,075
Operating income (loss)		(409	)		1,509			295			(1,823	)		(1,029	)		(846	)		(1,001	)		(2,194	)
Interest and other income, net		249			189			192			207			98			143			98			95
Income (loss) before income taxes and equity loss in investee		(160	)		1,698			487			(1,616	)		(931	)		(703	)		(903	)		(2,099	)
Provision for (benefit from) income taxes		(38	)		61			7			13			888			(318	)		(100	)		(434	)
Income (loss) before equity loss in investee		(122	)		1,637			480			(1,629	)		(1,819	)		(385	)		(803	)		(1,665	)
Equity loss in investee		(174	)		(175	)		(149	)		(279	)		(234	)		(210	)		(246	)		(245	)
Net income (loss)	$	(296	)	$	1,462		$	331		$	(1,908	)	$	(2,053	)	$	(595	)	$	(1,049	)	$	(1,910	)

Net income (loss) per common share:
Basic	$	(0.01	)	$	0.08		$	0.02		$	(0.10	)	$	(0.11	)	$	(0.03	)	$	(0.06	)	$	(0.11	)
Diluted	$	(0.01	)	$	0.08		$	0.02		$	(0.10	)	$	(0.11	)	$	(0.03	)	$	(0.06	)	$	(0.11	)

Summary of Significant Accounting Policies - Roll-Forward of Activity in Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Receivables [Abstract]
Allowance for doubtful accounts at beginning of year	$ 590	$ 287
Bad debt expense	189	309
Deductions	(28)	(6)
Allowance for doubtful accounts at end of year	$ 751	$ 590

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019 USD ($) Customer Segment	Dec. 31, 2018 USD ($) Customer	Jan. 01, 2019 USD ($)	Jan. 01, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Impairment losses of long-lived assets	$ 0
Number of reporting segments \| Segment	1
Shipping and handling fees incurred	$ 0
Type of Cost, Good or Service [Extensible List]	us-gaap:ShippingAndHandlingMember
Receivables from contract with customers	$ 6,555,000	$ 5,948,000
Contract with customer liability, revenue recognized	$ 59,000	16,000
Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations	true
Operating lease liabilities	$ 2,676,000		$ 3,000,000
Right-of-use assets	2,633,000		$ 3,000,000
Other Current Assets
Summary Of Significant Accounting Policies [Line Items]
Contract assets from contract with customers	150,000	150,000
Accrued Liabilities
Summary Of Significant Accounting Policies [Line Items]
Contract liabilities from contract with customers	$ 365,000	$ 166,000
Accounting Standards Update 2014-09
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, adjustment to accumulated deficit and accounts receivable				$ 327,000
Adjustment to accumulated deficit and deferred taxes				$ (74,000)
Computer Software
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets	3 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets	3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets	5 years
Customer Concentration Risk \| Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	1	1
Customer Concentration Risk \| Revenue \| Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	28.00%	13.00%
Customer Concentration Risk \| Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer		1
Customer Concentration Risk \| Accounts Receivable \| Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		18.00%
Customer Concentration Risk \| Accounts Receivable \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	0
Concentration risk, percentage	10.00%

Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 8,387	$ 10,347	$ 8,424	$ 5,370	$ 5,673	$ 5,625	$ 5,400	$ 4,653	$ 32,528	$ 21,351
Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Type of Revenue [Extensible List]									flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember
Revenue from contracts with customers by payor type									$ 32,528	$ 21,351
Accounting Standards Update 2014-09 \| Clinical Institutional Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type									31,284	19,980
Accounting Standards Update 2014-09 \| Clinical Patient Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type									539	547
Accounting Standards Update 2014-09 \| Clinical Insurance Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type									$ 705	$ 824

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	$ 58,124	$ 30,776
Marketable securities, Unrealized Gains	159	12
Marketable securities, Unrealized Losses	(32)	(104)
Marketable securities, Aggregate Fair Value	58,251	30,684
Cash and cash equivalents	11,965	6,736
Less: Cash equivalents	(6,399)	(2,692)
Short-Term Marketable Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	16,263	24,393
Marketable securities, Unrealized Gains	43	1
Marketable securities, Unrealized Losses	(2)	(96)
Marketable securities, Aggregate Fair Value	16,304	24,298
Short-Term Marketable Securities \| Money Market Accounts
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	4,700	2,692
Cash and cash equivalents fair value disclosure	4,700	2,692
Short-Term Marketable Securities \| Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	17,962	22,613
Marketable securities, Unrealized Gains	43	1
Marketable securities, Unrealized Losses	(2)	(96)
Marketable securities, Aggregate Fair Value	18,003	22,518
Short-Term Marketable Securities \| United States Treasury
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis		990
Marketable securities, Aggregate Fair Value		990
Short-Term Marketable Securities \| U.S. Government Agency Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis		790
Marketable securities, Aggregate Fair Value		790
Long-Term Marketable Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	41,861	6,383
Marketable securities, Unrealized Gains	116	11
Marketable securities, Unrealized Losses	(30)	(8)
Marketable securities, Aggregate Fair Value	41,947	6,386
Long-Term Marketable Securities \| Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	41,861	6,383
Marketable securities, Unrealized Gains	116	11
Marketable securities, Unrealized Losses	(30)	(8)
Marketable securities, Aggregate Fair Value	$ 41,947	$ 6,386

Marketable Securities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]
Gross unrealized loss	$ 32,000	$ 104,000

Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 58,251	$ 30,684
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	64,650	33,376
Fair Value Measurements Recurring \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	4,700	2,692
Fair Value Measurements Recurring \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	59,950	30,684
Fair Value Measurements Recurring \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	59,950	28,904
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	59,950	28,904
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring \| Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	4,700	2,692
Fair Value Measurements Recurring \| Money Market Accounts \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	4,700	2,692
Fair Value Measurements Recurring \| Money Market Accounts \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	0	0
Fair Value Measurements Recurring \| Money Market Accounts \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	$ 0	0
Fair Value Measurements Recurring \| United States Treasury
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		990
Fair Value Measurements Recurring \| United States Treasury \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		0
Fair Value Measurements Recurring \| United States Treasury \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		990
Fair Value Measurements Recurring \| United States Treasury \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		0
Fair Value Measurements Recurring \| U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		790
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		0
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		790
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities		$ 0

Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair value asset, investments measured using unobservable inputs	$ 0	$ 0
Fair value assets, transfers between levels, amount	0	0
Unrealized losses for securities in an unrealized loss position for more than 12 months	0
Other-than-temporary impairment losses related to marketable securities	$ 0	$ 0

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 13,964	$ 12,332
Less: Accumulated depreciation	(7,990)	(5,886)
Fixed assets, net	5,974	6,446
Computer Hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,705	1,579
Useful life in years	3 years
Computer Software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 541	495
Useful life in years	3 years
Medical Lab Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 10,493	8,136
Useful life in years	5 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 235	233
Useful life in years	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 876	802
Useful life in years	Shorter of lease term or estimated useful life
Assets Not Yet Placed in Service
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 114	$ 1,087

Fixed Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Depreciation expense on fixed assets	$ 2,107	$ 2,163

Other Current Assets - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Reagents	$ 277	$ 314
Contract assets	150	150
Prepaid expenses	1,288	556
Prepaid income taxes	46	1,251
Marketable securities interest receivable	478	220
Other receivable	16	70
Total	$ 2,255	$ 2,561

Reporting Segment and Geographical Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019 Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 8,387	$ 10,347	$ 8,424	$ 5,370	$ 5,673	$ 5,625	$ 5,400	$ 4,653	$ 32,528	$ 21,351
United States
Segment Reporting Information [Line Items]
Revenue									25,014	12,579
Canada
Segment Reporting Information [Line Items]
Revenue									2,245	3,984
Other Countries
Segment Reporting Information [Line Items]
Revenue									$ 5,269	$ 4,788

Commitments and Contingencies - Additional Information (Details) - Reagents $ in Millions	Dec. 31, 2019 USD ($)
Commitments And Contingencies [Line Items]
Non-cancelable purchase obligations	$ 2.9
Non-cancelable purchase obligations, payable within twelve months	1.5
Non-cancelable purchase obligations, payable within next twenty-four months	$ 1.4

Leases - Additional Information (Details) - USD ($)			12 Months Ended
Leases - Additional Information (Details) - USD ($)	Sep. 01, 2019	Aug. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019
Lessee Lease Description [Line Items]
Operating leases term of expiration			2023-08
Operating leases, renewal term			3 years
Rent expense, including sublease			$ 548,000	$ 418,000
Long-term ROU assets			2,633,000		$ 3,000,000
Short-term lease liabilities			420,000		384,000
Long-term lease liabilities			2,256,000		$ 2,600,000
Accounting Standards Update 2016-02
Lessee Lease Description [Line Items]
Impact to retained earnings upon adoption of new accounting standard			$ 0
Georgia
Lessee Lease Description [Line Items]
Long-term ROU assets	$ 110,000
Short-term lease liabilities	23,000
Long-term lease liabilities	$ 87,000
Lease termination date		August 31, 2019
New lease commencement date	Sep. 01, 2019

Leases - Schedule of Operating Lease Expense (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease cost	$ 587

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 535
Noncash lease expense	413
Right-of-assets obtained in exchange for new operating lease liabilities	$ 110

Leases - Schedule of Supplemental Information Related to Leases (Details)	Dec. 31, 2019
Leases [Abstract]
Weighted average remaining lease term - operating leases	5 years 7 months 6 days
Weighted average discount rate - operating leases	6.25%

Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
2020	$ 575
2021	591
2022	597
2023	567
2024	330
Thereafter	532
Total lease payments	3,192
Less imputed interest	(516)
Total	$ 2,676	$ 3,000

Leases - Schedule of Future Minimum Payments for Noncancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 560
2020	559
2021	550
2022	558
2023	567
Thereafter	862
Total minimum payments	$ 3,656

Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 3,209	$ 2,304
Cost of Revenue
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	676	523
Research and Development
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	1,024	732
Selling and Marketing
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	845	460
General and Administrative
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 664	$ 589

Equity-Based Compensation - Summary of Activity for Options to Acquire Common Shares (Details) - Options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units/Shares Subject to Options, Beginning Balance	417	465
Number of Units/Shares Subject to Options, Granted	30	10
Number of Units/Shares Subject to Options, Exercised	(100)	(40)
Number of Units/Shares Subject to Options, Canceled	(6)	(18)
Number of Units/Shares Subject to Options, Ending Balance	341	417	465
Number of Units/Shares Subject to Options, Exercisable	284
Weighted-Average Exercise Price Per Shares, Beginning Balance	$ 0.64	$ 0.84
Weighted-Average Exercise Price Per Shares, Granted	6.98	3.93
Weighted-Average Exercise Price Per Shares, Exercised	0.38	0.38
Weighted-Average Exercise Price Per Shares, Canceled	0.38	8.19
Weighted-Average Exercise Price Per Shares, Ending Balance	1.27	0.64	$ 0.84
Weighted-Average Exercise Price Per Shares, Exercisable	0.64
Weighted-Average Grant Date Fair Value, Granted	4.58	2.92
Weighted-Average Grant Date Fair Value, Exercised	5.36	5.80
Weighted-Average Grant Date Fair Value, Canceled	$ 7.10	$ 8.47
Weighted-Average Remaining Contractual Life (in years)	6 years 4 months 24 days	7 years 1 month 6 days	8 years
Weighted-Average Remaining Contractual Life (in years), Exercisable	6 years
Aggregate Intrinsic Value, Balance	$ 3,960	$ 1,116	$ 1,785
Aggregate Intrinsic Value, Exercisable	$ 3,482

Equity-Based Compensation - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of options vested	$ 549,000	$ 645,000
Unrecognized compensation expense	$ 146,000
Expected to be recognized, weighted-average period	6 months
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected to be recognized, weighted-average period	2 years 10 months 24 days	2 years 10 months 24 days
Total compensation cost not yet recognized on grant date	$ 6,900,000	$ 2,400,000
Compensation cost not yet recognized on grant date, period for recognition	4 years
Unrecognized compensation expense	$ 8,700,000	$ 5,600,000

Equity-Based Compensation - Summary of Activity for RSUs Relating to Shares of Company's Common Stock (Details) - Restricted Stock Units (RSUs) - 2016 Omnibus Incentive Plan - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Shares
Number of Shares, Beginning Balance	1,086	937
Number of Shares, Granted	982	554
Number of Shares, Vested and settled	(434)	(285)
Number of Shares, Forfeited	(123)	(120)
Number of Shares, Ending Balance	1,511	1,086
Weighted-Average Grant-Date Fair Value, Balance	$ 5.94	$ 7.39
Weighted-Average Grant-Date Fair Value, Granted	7.00	4.39
Weighted-Average Grant-Date Fair Value, Vested and settled	6.39	7.78
Weighted-Average Grant-Date Fair Value, Forfeited	5.38	5.77
Weighted-Average Grant-Date Fair Value, Balance	$ 6.54	$ 5.94

Equity-Based Compensation - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Options to Acquire Shares of Company's Common Stock (Details) - Options	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days
Risk-free interest rates	1.80%	2.80%
Expected volatility	73.60%	87.40%

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Line Items]
Federal statutory income tax rate	21.00%	21.00%
Valuation allowance	$ 2,125,000	$ 1,448,000
Increase in valuation allowance	(529,000)	(1,331,000)
Accrual for interests or penalties	0	0
Interest or penalties recognized	$ 0	$ 0
Earliest Tax Year
Income Taxes [Line Items]
Years subject to income tax examination	2016
Latest Tax Year
Income Taxes [Line Items]
Years subject to income tax examination	2019
Research and Development Credits and Depreciation Adjustments
Income Taxes [Line Items]
Increase in valuation allowance	$ 677,000
Federal
Income Taxes [Line Items]
Net operating loss carryforwards	1,600,000
Net operating loss not subject to expiration	1,600,000
State
Income Taxes [Line Items]
Net operating loss carryforwards	$ 1,900,000
Net operating loss carryforwards expiration beginning year	2022
Net operating loss carryforwards expiration ending year	2039

Income Taxes - Summary of Income (Loss) Before Income Taxes and Equity Loss in Investee (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
U.S. income (loss) before income taxes and equity loss in investee									$ 679	$ (4,602)
Foreign income (loss) before income taxes and equity loss in investee									(270)	(34)
Income (loss) before income taxes and equity loss in investee	$ (160)	$ 1,698	$ 487	$ (1,616)	$ (931)	$ (703)	$ (903)	$ (2,099)	$ 409	$ (4,636)

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Current:
Federal									$ 5
State									38
Total Current									43
Deferred:
Federal									(249)	$ (987)
State									(280)	(308)
Change in valuation allowance									529	1,331
Total Deferred										36
Total income tax expense (benefit)	$ (38)	$ 61	$ 7	$ 13	$ 888	$ (318)	$ (100)	$ (434)	$ 43	$ 36

Income Taxes - Reconciliation of Difference between Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Tax provision at federal statutory rate	21.00%	21.00%
State taxes	(46.76%)	4.37%
Foreign tax rate differential	13.83%
Stock based compensation	(53.53%)	(4.08%)
Return to provision	(57.11%)	2.31%
Meals and entertainment	3.87%	(0.13%)
Other	0.01%	(0.22%)
Change in valuation allowance	129.22%	(23.90%)
Tax provision	10.53%	(0.65%)

Income Taxes - Summary of Elements of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets
Accrued vacation and other accrued expenses	$ 97	$ 118
Provision for bad debts	180	136
Net operating losses	445	699
Stock based compensation	609	579
Unrealized loss on investments		21
State income taxes	8	9
Foreign	545	343
Credits	680	261
Lease liability	643
Gross deferred tax assets	3,207	2,166
Less: Valuation allowance	(2,125)	(1,448)
Net deferred tax assets	1,082	718
Deferred tax liabilities
Depreciation	419	644
Right of use asset	633
Other	30	74
Total deferred tax liabilities	$ 1,082	$ 718

Loss Per Share - Reconciliation of Basic and Diluted Loss Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Net loss	$ (296)	$ 1,462	$ 331	$ (1,908)	$ (2,053)	$ (595)	$ (1,049)	$ (1,910)	$ (411)	$ (5,607)
Weighted-average common shares - outstanding, basic									18,709	17,978
Weighted-average common shares - outstanding, diluted									18,709	17,978
Net loss per common share, basic	$ (0.01)	$ 0.08	$ 0.02	$ (0.10)	$ (0.11)	$ (0.03)	$ (0.06)	$ (0.11)	$ (0.02)	$ (0.31)
Net loss per common share, diluted	$ (0.01)	$ 0.08	$ 0.02	$ (0.10)	$ (0.11)	$ (0.03)	$ (0.06)	$ (0.11)	$ (0.02)	$ (0.31)

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

+ Details

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Loss Per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Loss Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted income (loss) per share	36	413
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted income (loss) per share	161	857

Retirement Plans - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan Disclosure [Line Items]
Company matching contributions to the 401(k) plan	$ 237,000	$ 176,000
Maximum
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, percent of match	3.00%

Related Party - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Apr. 30, 2017
Related Party Transaction [Line Items]
Ownership percentage	30.00%	30.00%
Xilong Scientific
Related Party Transaction [Line Items]
Ownership percentage of common stock outstanding shares	9.00%
Foundation
Related Party Transaction [Line Items]
Revenue from related parties	$ 16,000	$ 33,000
Due from related parties		0
Foundation \| Research Testing Services
Related Party Transaction [Line Items]
Revenue from related parties		0
University
Related Party Transaction [Line Items]
Revenue from related parties	53,000	66,000
Due from related parties	$ 39,000	51,000
FF Gene Biotech \| FJIP
Related Party Transaction [Line Items]
Ownership percentage			19.00%
FF Gene Biotech \| Dr. Han Lin Gao \| FJIP
Related Party Transaction [Line Items]
Ownership percentage	25.00%
Fulgent Pharma
Related Party Transaction [Line Items]
Due from related parties	$ 26,000	$ 22,000

Equity Method Investments - Additional Information (Details)	1 Months Ended	12 Months Ended
	Apr. 30, 2017 CNY (¥)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2019 CNY (¥)
Schedule Of Equity Method Investments [Line Items]
Ownership interest to be made in joint venture		30.00%	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 60,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	30.00%	30.00%	30.00%	30.00%
Contributions remain for joint venture		$ 5,600,000		¥ 39,300,000
Contributions made to joint venture \| $		137,000	$ 510,000
FF Gene Biotech \| Equipment
Schedule Of Equity Method Investments [Line Items]
Contributions made to joint venture \| $		$ 3,100,000
Xilong Scientific \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 102,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	51.00%
FJIP \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 19,000,000
Contribution period in joint venture	10 years
Previous contribution period in joint venture	5 years
Ownership interest to be made in joint venture	19.00%

Equity Method Investments - Schedule of Equity Method Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Apr. 30, 2017
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 872	$ 1,512
Ownership percentage	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 872	$ 1,512
Ownership percentage	30.00%	30.00%	30.00%

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Balance Sheet Data (Details) - FF Gene Biotech - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 3,007	$ 1,916
Non-current assets	4,457	4,068
Current liabilities	3,748	2,415
Non-current liabilities	889
Minority interest	(426)
Stockholders' equity	$ 3,253	$ 3,569

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Statement of Operations Data (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Equity Method Investments [Line Items]
Equity loss in investee	$ (174)	$ (175)	$ (149)	$ (279)	$ (234)	$ (210)	$ (246)	$ (245)	$ (777)	$ (935)
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Net sales									4,055	1,254
Gross profit									1,354	67
Net loss									(3,009)	(3,101)
Equity loss in investee									$ (777)	$ (935)

Equity Distribution Agreement - Additional Information (Detail) - Equity Distribution Agreement - Common Stock - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2019	Dec. 31, 2019
Equity Distribution Agreement [Line Items]
Number of shares sold		104,390
Sale of stock, weighted average selling price per share		$ 12.14
Net proceeds from sale of stock		$ 979,000
Maximum
Equity Distribution Agreement [Line Items]
Aggregate offering price	$ 30,000,000
Percentage of commission to be paid from gross proceeds	3.00%

Underwriting Agreement - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Nov. 13, 2019	Dec. 31, 2019
Underwriting Agreement [Line Items]
Net proceeds from sale of stock		$ 28,758
Purchase Agreement \| Common Stock
Underwriting Agreement [Line Items]
Number of shares sold	2,673,750
Selling price per share	$ 10.51875
Public offering price per share	$ 11.25
Net proceeds from sale of stock	$ 27,600
Payments of underwriting discounts and commissions and offering expenses	$ 2,400

Selected Quarterly Financial Data (Unaudited) - Unaudited Quarterly Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Statement of Operations Data:
Revenue	$ 8,387	$ 10,347	$ 8,424	$ 5,370	$ 5,673	$ 5,625	$ 5,400	$ 4,653	$ 32,528	$ 21,351
Cost of revenue	3,634	3,885	3,620	2,968	2,769	2,612	2,544	2,772	14,107	10,697
Gross profit	4,753	6,462	4,804	2,402	2,904	3,013	2,856	1,881	18,421	10,654
Operating expenses:
Research and development	1,795	1,744	1,574	1,424	1,426	1,438	1,212	1,458	6,537	5,534
Selling and marketing	1,635	1,687	1,304	1,272	1,128	1,115	1,279	1,130	5,898	4,652
General and administrative	1,732	1,522	1,631	1,529	1,379	1,306	1,366	1,487	6,414	5,538
Total operating expenses	5,162	4,953	4,509	4,225	3,933	3,859	3,857	4,075	18,849	15,724
Operating income (loss)	(409)	1,509	295	(1,823)	(1,029)	(846)	(1,001)	(2,194)	(428)	(5,070)
Interest and other income, net	249	189	192	207	98	143	98	95	837	434
Income (loss) before income taxes and equity loss in investee	(160)	1,698	487	(1,616)	(931)	(703)	(903)	(2,099)	409	(4,636)
Provision for (benefit from) income taxes	(38)	61	7	13	888	(318)	(100)	(434)	43	36
Income (loss) before equity loss in investee	(122)	1,637	480	(1,629)	(1,819)	(385)	(803)	(1,665)	366	(4,672)
Equity loss in investee	(174)	(175)	(149)	(279)	(234)	(210)	(246)	(245)	(777)	(935)
Net income (loss)	$ (296)	$ 1,462	$ 331	$ (1,908)	$ (2,053)	$ (595)	$ (1,049)	$ (1,910)	$ (411)	$ (5,607)
Net income (loss) per common share:
Basic	$ (0.01)	$ 0.08	$ 0.02	$ (0.10)	$ (0.11)	$ (0.03)	$ (0.06)	$ (0.11)	$ (0.02)	$ (0.31)
Diluted	$ (0.01)	$ 0.08	$ 0.02	$ (0.10)	$ (0.11)	$ (0.03)	$ (0.06)	$ (0.11)	$ (0.02)	$ (0.31)